Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme
Author:
Funder
Novartis
Pfizer
Roche
Sanofi
Bayer
Astellas
Astex
PharmaMar
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference12 articles.
1. Committee for medicinal products for human use (CHMP) European medicines agency,2011
2. Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer;Steven;Clin Pharmacokinet,2017
3. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients;Carton;Eur J Canc,2017
4. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer;van Nuland;Prostate Cancer Prostatic Dis,2019
5. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer;Chi;J Clin Pharmacol,2015
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib;Clinical and Translational Science;2023-10-12
2. Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate;Pharmaceutical Research;2023-10-11
3. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study;Annals of Oncology;2022-10
4. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products;European Journal of Pharmaceutical Sciences;2022-09
5. Is Low-Dose Abiraterone for Prostate Cancer An Attractive Strategy for Limited Resource Settings?;Indian Journal of Medical and Paediatric Oncology;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3